01:24 AM EDT, 07/30/2026 (MT Newswires) -- UCB (UCB.BR) reported on Thursday that its attributable profit and revenue in the first half increased year over year. Profit attributable to equity holders for the six months ended June 30 was 1.11 billion euros, compared with 475 million euros earlier. EPS moved to 5.73 euros from 2.44 euros. The biopharmaceutical company's revenue was 4.27 billion euros, compared with 3.49 billion euros a year ago. For full-year 2026, the company expects revenue growth in the low-teens to mid-teens percentage range at constant exchange rates.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.